<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03027076</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00089692</org_study_id>
    <nct_id>NCT03027076</nct_id>
  </id_info>
  <brief_title>Microbiome of Urologic Chronic Pelvic Pain Syndrome</brief_title>
  <official_title>Microbiome Studies of Urologic Chronic Pelvic Pain Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is being done to learn more about the bacteria that live in the genito-urinary&#xD;
      tract in subjects with urologic chronic pelvic pain syndrome (UCPPS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research is being done to learn more about the bacteria that live in the genito-urinary&#xD;
      tract in subjects with urologic chronic pelvic pain syndrome (UCPPS).&#xD;
&#xD;
      A microbiome is defined as &quot;the ecological community of commensal, symbiotic, and pathogenic&#xD;
      microorganisms that literally share our body space.&quot; (Lederberg, 2001) The present study is&#xD;
      designed to establish the prostate, urinary bladder and urethral microbiome in men with&#xD;
      chronic prostatitis/chronic pelvic pain syndrome or the urinary bladder and urethral&#xD;
      microbiome in women with interstitial cystitis/painful bladder syndrome.&#xD;
&#xD;
      The human urethra, bladder and prostate normally harbor microbial communities. The recent&#xD;
      advent of large-scale &quot;omics&quot; technologies allows a detailed analysis of those communities.&#xD;
      While current knowledge of the normal inhabitants of the human urogenital tract remains&#xD;
      incomplete, more than 90% of patients with UCPPS report the onset of symptoms following a&#xD;
      &quot;urinary tract infection&quot;. The causative agents in most of those cases remain unknown, partly&#xD;
      due to the limitations of older detection technologies that require the detection and&#xD;
      isolation of a single microorganism for implicating it as a causative agent. Furthermore,&#xD;
      many microbial species remain unculturable and therefore, are often undetectable using&#xD;
      standard technology.&#xD;
&#xD;
      The current project will utilize state-of-the-art &quot;omic&quot; technology to detect and identify&#xD;
      microbial species in the urethra and bladder of both men and women and the prostate of men.&#xD;
      Additionally, the inflammatory response that accompanies those microbial communities will be&#xD;
      characterized. Finally, the presence and number of microbial species will be correlated with&#xD;
      the intensity of the inflammatory response and the severity of symptoms that patients with&#xD;
      UCPPS experience.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Funding for project not secured&#xD;
  </why_stopped>
  <start_date type="Actual">November 2013</start_date>
  <completion_date type="Actual">January 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Microbiome</measure>
    <time_frame>Within 6 month period from baseline evaluation</time_frame>
    <description>Evaluate the microbiome at baseline, one &quot;good day&quot; (minimal or no symptoms) and one &quot;bad day&quot; (worst symptoms) within a 6 month period</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">0</enrollment>
  <condition>Prostatitis</condition>
  <condition>Chronic Prostatitis</condition>
  <condition>Interstitial Cystitis</condition>
  <condition>Painful Bladder Syndrome</condition>
  <condition>Bladder Pain Syndrome</condition>
  <arm_group>
    <arm_group_label>Men with UCPPS</arm_group_label>
    <description>Genitourinary Specimen Collection for microbiome evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asymptomatic Men</arm_group_label>
    <description>Genitourinary Specimen Collection for microbiome evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Women with UCPPS</arm_group_label>
    <description>Collect midstream urine samples</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Asymptomatic Women</arm_group_label>
    <description>Collect midstream urine samples</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Genitourinary Specimen Collection</intervention_name>
    <description>Collect urethral swab, urine before prostatic massage (pre-M), urine after prostatic massage (post-M) and Expressed Prostatic Secretion (EPS)</description>
    <arm_group_label>Asymptomatic Men</arm_group_label>
    <arm_group_label>Men with UCPPS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Collect midstream urine samples</intervention_name>
    <description>Collect midstream urine samples</description>
    <arm_group_label>Asymptomatic Women</arm_group_label>
    <arm_group_label>Women with UCPPS</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      1. Urine from male and female participants&#xD;
&#xD;
        2. Expressed prostatic secretions (EPS) from male participants&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Community Sample&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consent: Participant has signed and dated the Informed Consent document, approved by&#xD;
             the Johns Hopkins Medical Institutions Institutional Review Board;&#xD;
&#xD;
          -  Agreement: Participant agrees to participate in study procedures;&#xD;
&#xD;
          -  Age: Participant is at least 18 years of age;&#xD;
&#xD;
          -  Symptom Severity: Participant reports a response of at least 8 on the Pain Domain of&#xD;
             the NIH-Chronic Prostatitis Symptom Index (CPSI) Questionnaire;&#xD;
&#xD;
          -  Duration of Symptoms: Symptoms have been present for at least 3 months within the&#xD;
             preceding 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Urethral conditions: Participant has an ongoing symptomatic urethral stricture;&#xD;
&#xD;
          -  Bladder conditions: Participant has a history of cystitis caused by tuberculosis,&#xD;
             radiation therapy or cytoxan/cyclophosphamide therapy, augmentation cystoplasty or&#xD;
             cystectomy;&#xD;
&#xD;
          -  Testicular conditions: Participant diagnosed with unilateral orchialgia, without&#xD;
             pelvic symptoms;&#xD;
&#xD;
          -  Prostate conditions or procedures: Participant has a history of transurethral&#xD;
             microwave thermotherapy (TUMT), transurethral needle ablation (TUNA), balloon&#xD;
             dilation, prostate cryosurgery, or laser procedure;&#xD;
&#xD;
          -  Neurological diseases or disorders affecting the bladder: Parkinson disease, multiple&#xD;
             system atrophy, multiple sclerosis, spinal cord injury, cervical myelopathy, acute&#xD;
             transverse myelitis, diabetic cystopathy, or dysfunctional voiding (non-neurogenic&#xD;
             neurogenic bladder or Hinman syndrome);&#xD;
&#xD;
          -  Psychiatric conditions: Participant has current major psychiatric disorder or other&#xD;
             psychiatric or medical issues that would interfere with study participation (e.g.&#xD;
             dementia, psychosis, upcoming major surgery, etc.);&#xD;
&#xD;
          -  Malignancy: Participant has a history of cancer (with the exception of skin cancer).&#xD;
&#xD;
        Control group exclusion criteria:&#xD;
&#xD;
        In addition to the exclusion criteria listed above, additional criteria for control&#xD;
        subjects are as follows:&#xD;
&#xD;
          -  Chronic Pain: In the past year, symptoms of discomfort or pain in the pelvic region&#xD;
             for a period longer than 3 months within the preceding year;&#xD;
&#xD;
          -  Infection: Volunteers who have had a urinary tract infection with a urine culture&#xD;
             value of &gt;100,000 colony forming units/ml (CFU/ml) within the past three months.&#xD;
&#xD;
          -  Intravesical Therapy: Volunteers treated with intravesical chemotherapy or Bacillus&#xD;
             Calmette-Guerin (BCG) therapy;&#xD;
&#xD;
          -  Gastrointestinal Conditions: Volunteers with inflammatory bowel disease (such as&#xD;
             Crohn's disease or ulcerative colitis, but not irritable bowel syndrome).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arthur L Burnett, MD, FACS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>January 18, 2017</study_first_submitted>
  <study_first_submitted_qc>January 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2017</study_first_posted>
  <last_update_submitted>August 28, 2017</last_update_submitted>
  <last_update_submitted_qc>August 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prostatitis</keyword>
  <keyword>chronic prostatitis</keyword>
  <keyword>chronic pelvic pain syndrome</keyword>
  <keyword>interstitial cystitis</keyword>
  <keyword>painful bladder syndrome</keyword>
  <keyword>bladder pain syndrome</keyword>
  <keyword>biomarkers</keyword>
  <keyword>biological markers</keyword>
  <keyword>bacteria</keyword>
  <keyword>microbiome</keyword>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystitis</mesh_term>
    <mesh_term>Cystitis, Interstitial</mesh_term>
    <mesh_term>Prostatitis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Pelvic Pain</mesh_term>
    <mesh_term>Somatoform Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

